ABL Diagnostics Discloses Voting and Share Information

ABL Diagnostics, a company based in Woippy and listed on Euronext Paris, has released information regarding its share capital and voting rights as of May 22, 2026. The company has a total of 16,114,656 shares composing its share capital. These shares provide a theoretical total of 30,846,644 voting rights, with 30,814,120 of these votes being exercisable. Notably, ABL Diagnostics grants double voting rights to shares held by the same shareholder for over two years, following resolutions made on March 23, 2022.

ABL Diagnostics specializes in molecular biology tests and markets products globally through its sales network. The company offers advanced detection solutions covering HIV drug resistance, SARS-CoV-2, and other microbiology applications. ABLD continues to expand its portfolio, emphasizing recurrent revenue from robust microbiological applications.